Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that its Dupixent has been ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, ...